Phastar Scoops Multiple Finalist Positions in 2025 SCRIP Awards
Shortlisted in the ‘Best Contract Research Organization – Specialist Providers’ & ‘Community Partnership of the Year’
London, UK, and Durham (NC), US – October 1st, 2025: Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been named as finalists in two categories at the prestigious 2025 SCRIP Awards.
Phastar was recognized in the ‘Best Contract Research Organization – Specialist Providers’ and ‘Community Partnership of the Year’ categories at the 21st anniversary awards, which will be announced at a ceremony at the London Hilton on Park Lane on the 11th of December 2025.
Having taken home the trophy in 2024, Phastar was again shortlisted in the ‘Best Contract Research Organization – Specialist Providers’ category for its application of advanced methodologies, AI-enhanced analytics, and tailored tools in clinical research, alongside its commitment to leading the CRO industry in Corporate Responsibility and ESG practices. Fundamental to securing the finalist spot was Phastar’s Clinical Intelligence platform which gives clients access to advanced tools that enhance insight gathering across teams. Developments within the platform include a Recruitment Forecasting app and an RBQM app, offering the capability to securely aggregate data from disparate sources and formats. Offering bespoke solutions and automated processes, the platform ensures real-time data access for effective, accelerated decision-making.
Phastar scooped a finalist spot in the ‘Community Partnership of the Year’ for its collaboration with Medicines Development for Global Health (MDGH), a not-for-profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most, on its mission to eradicate onchocerciasis (river blindness). Through the Phastar CARES pro bono scheme, Phastar provided biometrics expertise as MDGH conducted two double-blind Phase IIIb clinical studies involving more than 12,000 participants. This led to moxidectin becoming the first new medicine registered for onchocerciasis in more than 30 years and since September 2025, moxidectin has been included in the 2025 World Health Organization Model List of Essential Medicines and Model List of Essential Medicines for Children.
Speaking about the news, Phastar’s CEO, Graham Clark, commented: “We are absolutely honored to be finalists, once again, at the prestigious SCRIP Awards. Earning recognition in both the ‘Best Contract Research Organization – Specialist Providers’ and ‘Community Partnership of the Year’ categories, alongside industry leaders, is first and foremost a celebration of Phastar’s people.
Securing shortlist spots in multiple categories is a testament to the expertise, dedication, and innovation that our employees demonstrate every day – delivering exceptional results for our clients and building partnerships that truly make a difference. This recognition highlights not only their commitment to excellence and drive to make a positive impact, but also our shared belief in doing the right thing — leading with corporate responsibility and working together to deliver better health outcomes for patients globally.”
For further information on Phastar’s solutions, please visit here.
-END-
About Phastar
Phastar is an award-winning biometric and data science contract research organization (CRO), trusted by pharma, biotech, and medical device companies worldwide. With a global team of data specialists, we bring expertise, precision, and pace to every trial- because behind every data point is a patient waiting for treatment.
We don’t just deliver high-quality clinical trial data; we partner with you to turn complexity into clarity. Leveraging technology, AI-enhanced analytics, advanced statistical methods, and deep therapeutic expertise, we accelerate regulatory approvals, ensure compliance with global standards, and mitigate risk.
Our proven track record in transforming complex data into clear, actionable intelligence enables you to accelerate drug development. With scalable, tailored solutions, we expedite trials- bringing life-changing therapies to patients faster.